Force of contraction

Ncardia’s Cardio.Force platform offers a non-invasive in vitro assay to measure true contractility of human cardiomyocytes with exceptional accuracy under physiological mechanical boundary conditions. The assay uses monolayers of human cardiomyocytes. Also, co-cultures of the cardiomyocytes with cardiac fibroblasts can be applied.

This is the only in vitro contraction assay that mimics physiological tissue elasticity in a multi well format enabling studying compound effects in e.g. cardiomyopathy, or in healthy cardiomyocytes for safety assessment.


How it works

hiPSC-derived cardiomyocytes are cultured on Cardio.Force plates featuring a flexible culture substrate composed of a ultra-thin silicone membrane. Together with these culture plates the custom made assay system allows for measurements and quantification of the contraction-induced deflection of the silicone membranes. This is facilitated by a combination of capacitive distance sensors and a pressure sensors beneath the membrane of each well. All measurements are performed in a cell culture incubator at 37°C and 5% CO2.


Get inspired


Inotropic compounds change the force of heart muscle contraction. Positive inotropes, that strengthen the contraction, can be used for patients with cardiomyopathy. Negative inotropes, that weakens the contraction, are used for hypertension, arrhythmia, and angina.

Assessment of hiPSC-derived cardiomyocytes on the Cardio.Force, demonstrates the positive inotrope effect of isoproterenol, and the negative inotrope effect of verapamil.

Related information

Safety Service  

Biomarker service

Structural toxicity analysis


Studying inotropic compounds effects in human iPSC-derived cardiomyocytes using 2D and 3D models